VDmax Method Explained
The VDmax method is a dose substantiation approach used in radiation sterilisation to demonstrate that a selected sterilisation dose can achieve the required Sterility Assurance Level (SAL).
Rather than treating sterilisation dose as a generic number, the VDmax approach connects the selected dose with the product's microbiological characteristics and supporting evidence. It therefore forms an important part of the radiation sterilisation framework under ISO 11137.
What Is the VDmax Method?
VDmax is used when a manufacturer has a preselected sterilisation dose and needs to substantiate that dose for the product. The methodology uses a verification dose and microbiological evaluation to provide evidence supporting the selected sterilisation dose.
Key distinction: VDmax is a dose substantiation methodology. It should not be interpreted as a universal rule that every product can simply be assigned a standard radiation dose.
VDmax25 and VDmax15
The published ISO 11137-2 framework includes approaches for substantiating selected sterilisation doses of 25 kGy and 15 kGy. These are commonly referred to as VDmax25 and VDmax15.
The broader selected-dose concept is also represented as VDmaxSD, where the selected sterilisation dose is identified as part of the method designation.
VDmax
Connecting product bioburden with evidence for a selected radiation sterilisation dose
THE CORE PRINCIPLE
A selected sterilisation dose is supported by microbiological evidence obtained using the applicable verification-dose methodology.
Integrated Outcome
Evidence Supporting the Selected Radiation Sterilisation Dose
Following dose establishment, routine sterilisation dose audits provide continued evidence that the established dose remains effective.
Why Bioburden Matters
VDmax is closely connected with the bioburden of the product. Bioburden represents the viable microorganisms associated with the product before sterilisation and therefore provides an important microbiological input to radiation sterilisation dose substantiation.
This is why VDmax should not be viewed simply as a calculation. The methodology sits within a broader process involving product definition, microbiological assessment, sterilisation dose establishment and subsequent routine control.
Where Does VDmax Fit Within ISO 11137?
ISO 11137 provides the overall framework for radiation sterilisation. Within that framework, dose establishment addresses how an appropriate sterilisation dose is determined or substantiated.
VDmax is therefore one part of a larger technical chain:
Product → Bioburden → Dose Substantiation → Validation → Routine Control
This relationship is particularly important when manufacturers introduce a new product, establish a new product family, change product configuration or evaluate a different sterilisation strategy.
VAPL Technical Perspective
For a medical device manufacturer evaluating gamma sterilisation, the important question is not simply: “Can we use VDmax?”
The more useful question is: “Does our product, bioburden profile, product family and selected sterilisation dose support an applicable VDmax approach?”
Answering that question requires the methodology to be considered alongside dose establishment, bioburden assessment, dose mapping, dosimetry and sterilisation validation.
VDmax Is Not a Universal Shortcut
One of the most important points for manufacturers to understand is that VDmax does not mean that every product can automatically be processed at 15 kGy or 25 kGy.
The suitability of a selected-dose approach depends on the applicable methodology and the characteristics of the product and its microbiological profile. Product family definition and appropriate supporting evidence are also important considerations.
The selected sterilisation dose must ultimately be demonstrated to achieve the required sterilisation objective while remaining compatible with the product's quality, safety and performance requirements.
VDmax and Routine Dose Audits
Dose substantiation is not the end of the sterilisation lifecycle. Once a sterilisation dose has been established, routine dose audits provide continuing evidence that the dose remains effective for the product under the applicable process conditions.
This is an important distinction between establishing a sterilisation dose and maintaining confidence in that dose over time.
Conclusion
The VDmax method provides a structured approach for substantiating a selected radiation sterilisation dose using microbiological evidence. VDmax25 and VDmax15 are established approaches within the published ISO 11137-2 framework, while the broader selected-dose methodology has also been developed through ISO 13004.
For manufacturers, the real value of VDmax lies in understanding how product definition, bioburden, selected dose, microbiological evidence and routine dose auditing work together as part of a controlled radiation sterilisation process.
Technical note: ISO 11137-2:2013 is the current published edition of Part 2. ISO/DIS 11137-2 is under development and may change the presentation and scope of selected-dose methodologies. Manufacturers should refer to the applicable current standard and their regulatory requirements when establishing or substantiating a sterilisation dose.
